UniQuest is Australia’s leading university commercialising entity, benchmarking in the top 10 percent globally for university-based technology transfer offices.
Since 1984, UniQuest has built, commercialised and managed an extensive intellectual property and asset portfolio, including more than 87 granted US patents and 80 companies resulting from university-based discoveries and expertise. Technologies licensed by UniQuest have resulted in more than $15.5 billion in gross product sales.
UniQuest was responsible for the commercialisation of the HPV vaccine Gardasil®, the Triple P Positive Parenting Program, the image correction technology used in two-thirds of the world's MRI machines and Spinifex Pharmaceuticals Pty Ltd – a biopharmaceutical company acquired recently in one of Australia's largest ever biotech deals.
QEDDI offers unique licensing opportunities from a pipeline of novel therapeutic, validated and de-risked drug leads, based on UQ’s most innovative biological research.
UniQuest has the experience to manage a systematic transition of QEDDI lead compounds into an industry partners' own clinical development pipeline.
Compounds will be accompanied by high quality data packages and solid IP protection.
Should you have an interest in QEDDI, please contact the team via email@example.com.